Clinical Vignette Series: Navigating the Evolving Treatment Landscape for HR-Positive Breast Cancer

Release Date: February 28, 2022

Expiration Date: February 28, 2023

Activity Overview

The management of hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer has changed dramatically over the last 10 years. Notable developments include the use of new biomarkers to guide treatment decisions and the introduction of targeted agents, used alone and in combination with endocrine therapy, for early-stage and advanced disease. Accumulating evidence continues to facilitate optimized use of available agents and to broaden understanding of how contemporary treatment strategies are changing the course of the disease. Promising novel agents, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs), may expand the therapeutic options for HR+/HER2- breast cancer.

In this Clinical Vignette activity, experts in the management of HR+/HER2- breast cancer answer questions and share perspectives about state-of-the-art management of HR+/HER2- breast cancer, including areas of clinical uncertainty, individualized treatment planning, and emerging agents that may further shift treatment paradigms. This interactive, online activity features a series of case-based vignettes, self-reflection questions, and brief audio clips in which the program faculty share their approaches to breast cancer care.

Target Audience

This educational activity is directed toward oncologists, oncology nurses, and specialty pharmacists interested in the treatment and management of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss the efficacy and safety of endocrine therapy, CDK4/6 inhibitors, PI3K inhibitors, and other targeted agents for the treatment of patients with HR+/HER2- breast cancer in the context of current treatment paradigms
• Develop personalized treatment plans for patients with HR+/HER2- breast cancer by incorporating tumor and patient characteristics with clinical data and expert guidelines, in order to optimize outcomes with targeted therapies
• Assess emerging data from clinical trials evaluating CDK4/6 inhibitors in the adjuvant setting for patients with high-risk, early-stage HR+/HER2- breast cancer, in conjunction with clinical and/or genomic strategies for estimating relapse risk to identify patients who may benefit from targeted combinations
• Explain clinical trial opportunities and emerging data with investigational agents for patients with HR+/HER2- breast cancer, particularly in areas of high clinically unmet need

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.